Drug approved to prevent seasonal affective disorder



Longtime sufferers of seasonal depression may now have a way to stop the winter blues before they start. The Food and Drug Administration (FDA) announced Monday that it has approved the prescription medication Wellbutrin XL to prevent major depressive episodes caused by seasonal affective disorder. The antidepressant is the first drug approved to treat the condition, which is estimated to affect as many as 10 million Americans each year.

In these people, low levels of sunlight during autumn and winter can trigger a depression that may last as long as six months. Common symptoms include fatigue, oversleeping, impaired social functioning, and weight gain. Doctors often use antidepressant medications and light therapy to treat seasonal affective disorder; now, GlaxoSmithKline, the manufacturer of Wellbutrin XL, will be able to market the drug expressly as a preventive measure that can be taken in the fall to head off symptoms.

MORE: USNews.com: Health: In Brief: Mental Health: Drug approved to prevent seasonal affective disorder

Related Posts with Thumbnails
Print Friendly

Speak Your Mind

*


*

NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.
Read previous post:
Depression and Diabetes: Which Comes First?

Whether depression tends to cause type 2 diabetes or diabetes causes depression has been a chicken vs. egg issue for...

Close